| Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye. | |
| | |
MedLine Citation:
|
PMID: 10219466 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF2a- isopropyl ester, CAS 130209-82-4 PhXA41, Xalatan) is a prodrug used for reduction of the intraocular pressure in the treatment of glaucoma. The pahrmacokinetics of this drug was studied in the cynomolgus monkey after intravenous, oral and topical administration of 9 beta-[3H] labelled latanoprost. The plasma profile of radioactivity from HPLC separation of samples obtained after intravenous as well as topical administration on the eyes showed a rapid and complete hydrolysis of the ester. The pharmacologically active acid of latanoprost showed a maximum concentration 5 min post topical administration and an elimination half-life of about 10 min. Tertiary butyldimethylsilyl derivatives were prepared of the radioactive fractions collected from the HPLC column. The derivatives were analysed by gas chromatography-mass spectrometry (GC-MS). After oral administration no latanoprost and very little of its acid was present in plasma, indicating a first-pass metabolism resulting in more polar compounds. Based on the retention times on the HPLC and GC and on a mass spectrum similar to the acid of latanoprost but 28 daltons lower, the main metabolite in urine and faeces was identified as the 1,2-dinor acid of latanoprost. In a similar way a more polar fraction from urine was identified as the 1,2,3,4-tetranor metabolite of the acid of latanoprost. The tissue distribution after i.v. and topical administration was similar with organs of metabolism (liver) and elimination (kidney) containing the highest concentrations. After topical application much of the dose was found in the anterior ocular tissues but not in the posterior parts of the eye. In conclusion, latanoprost is a prodrug which in vivo rapidly is hydrolysed to the corresponding free acid. The acid of latanoprost has a short half-life in plasma and is extensively metabolised mainly through beta-oxidation before it is excreted into the urine and faeces. |
| | |
Authors:
|
B Sjöquist; S Tajallaei; J Stjernschantz |
Related Documents
:
|
8406236 - Metabolism and pharmacokinetics of deuterium-labelled di-2-(ethylhexyl) adipate (deha) ... 12936706 - Mexiletine carbonyloxy beta-d-glucuronide: a novel metabolite in human urine. 22538726 - In vitro evaluation of polymeric micelles based on hydrophobically-modified sulfated ch... 318946 - Identification of urinary metabolites of sodium dipropylacetate in man; potential sourc... 10964726 - Mutation of the nucleophilic elbow of the lux-specific thioesterase from vibrio harveyi. 12926916 - Bound fumonisin b1: analysis of fumonisin-b1 glyco and amino acid conjugates by liquid ... |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Arzneimittel-Forschung Volume: 49 ISSN: 0004-4172 ISO Abbreviation: Arzneimittelforschung Publication Date: 1999 Mar |
Date Detail:
|
Created Date: 1999-06-07 Completed Date: 1999-06-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0372660 Medline TA: Arzneimittelforschung Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 225-33 Citation Subset: IM |
Affiliation:
|
Glaucoma Research Laboratories, Pharmacia & Upjohn AB, Upssala, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Administration, Topical Animals Biotransformation Chromatography, High Pressure Liquid Eye / metabolism* Feces / chemistry Female Gas Chromatography-Mass Spectrometry Injections, Intravenous Intraocular Pressure / drug effects* Macaca fascicularis Male Prodrugs / administration & dosage, pharmacokinetics* Prostaglandins F, Synthetic / administration & dosage*, pharmacokinetics* Tissue Distribution |
| Chemical | |
Reg. No./Substance:
|
0/Prodrugs; 0/Prostaglandins F, Synthetic; 130209-82-4/latanoprost |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropa...
Next Document: Pharmacokinetics of latanoprost in the cynomolgus monkey. 2nd communication: repeated topical admini...